Phillip Taboada1, Rohit R. Badia1, Dhillon Advano1, Andrew Murphy1, Christina Sze1, Ryan J. Mauck1, Jennifer Tse1, Jeffrey Gahan2, Claus G. Roehrborn1, Ramy Goueli1,*
Canadian Journal of Urology, Vol.32, No.5, pp. 491-499, 2025, DOI:10.32604/cju.2025.068150
- 30 October 2025
Abstract Background: Aquablation is a robotic-assisted, water jet-based transurethral therapy for benign prostatic hyperplasia (BPH). Concerns about postoperative hematuria led to the practice of limited transurethral resection (TUR) with cauterization. This study aimed to assess the impact of tranexamic acid (TXA) on hematuria outcomes when combined with limited TUR after Aquablation. Methods: We retrospectively analyzed men undergoing Aquablation at our institution (October 2020–July 2024). Demographic, prostate, surgical, and hematuria outcomes were extracted from electronic medical records. Kruskal-Wallis test compared medians. Results: Of 131 patients, 113 (86%) had limited TUR; 31 (27%) received 1 g TXA perioperatively. TXA… More >